Safety and immunogenicity of WRSd1, a live attenuated Shigella dysenteriae type 1 vaccine candidate

Vaccine

Volumn 26, Issue 26, 2008, Pages 3291-3296

  McKenzie, Robin ^a   Venkatesan, Malabi M ^b   Wolf, Marcia K ^b   Islam, Dilara ^c   Grahek, Shannon ^a   Jones, Andrea M ^a   Bloom, Arlene ^a   Taylor, David N ^a   Hale, Thomas L ^b   Bourgeois, A Louis ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

Author keywords

Live attenuated vaccine; S. dysenteriae; Shigella

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; LIPOPOLYSACCHARIDE; LIVE VACCINE; SHIGA TOXIN; SHIGELLA VACCINE; WRSD1 PROTEIN;

ABDOMINAL PAIN; ADULT; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM ISOLATION; CLINICAL TRIAL; DEFECATION URGENCY; DIARRHEA; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG SYNTHESIS; EPIDEMIC; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; GENE DELETION; GURGLING; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; MALAISE; MALE; NAUSEA; NORMAL HUMAN; PAIN; PANDEMIC; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SHIGELLA DYSENTERIAE; SHIGELLOSIS;

ADOLESCENT; ADULT; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; DIARRHEA; DNA-BINDING PROTEINS; FEMALE; GENE DELETION; HUMANS; IMMUNOGLOBULIN A; MALE; MIDDLE AGED; SHIGA TOXIN; SHIGELLA DYSENTERIAE; SHIGELLA VACCINES; TRANSCRIPTION FACTORS; VACCINES, ATTENUATED;

EID: 44749092472     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.03.079     Document Type: Article

References (29)

1. Kotloff K.L., Winickoff J.P., Ivanoff B., Clemens J.D., Swerdlow D.L., Sansonetti P.J., et al. Global burden of Shigella infections: Implications for vaccine development and implementation of control strategies. Bull World Health Organ 77 8 (1999) 651-666
2. WHO. Guidelines for the control of shigellosis, including epidemics due to Shigella dysenteriae 1. Geneva, Switzerland: World Health Organization; 2005.
3. Cherla R.P., Lee S.Y., and Tesh V.L. Shiga toxins and apoptosis. FEMS Microbiol Lett 228 November 21 (2) (2003) 159-166
4. Fontaine A., Arondel J., and Sansonetti P.J. Role of Shiga toxin in the pathogenesis of bacillary dysentery, studied by using a tox-mutant of Shigella dysenteriae 1. Infect Immun 56 December (12) (1988) 3099-3109
5. Ram P.K., Crump J.A., Gupta S.K., Miller M.A., and Mintz E.D. Part II. Analysis of data gaps pertaining to Shigella infections in low and medium human development index countries, 1984-2005. Epidemiol Infect August 9 (2007) 1-27
6. Mendizabal-Morris C.A., Mata L.J., Gangarosa E.J., and Guzman G. Epidemic Shiga-bacillus dysentery in Central America. Derivation of the epidemic and its progression in Guatemala, 1968-69. Am J Trop Med Hyg 20 November (6) (1971) 927-933
7. Reller L.B., Rivas E.N., Masferrer R., Bloch M., and Gangarosa E.J. Epidemic Shiga-bacillus dysentery in Central America. Evolution of the outbreak in El Salvador, 1969-70. Am J Trop Med Hyg 20 November (6) (1971) 934-940
8. Ebright J.R., Moore E.C., Sanborn W.R., Schaberg D., Kyle J., and Ishida K. Epidemic Shiga bacillus dysentery in central Africa. Am J Trop Med Hyg 33 November (6) (1984) 1192-1197
9. Basikila P., Male S., Lindgren J., and Goma Epidemiology Group. Public health impact of Rwandan refugee crisis: what happened in Goma, Zaire, in July, 1994?. Lancet 345 February 11 (8946) (1995) 339-344
10. Guerin P.J., Brasher C., Baron E., Mic D., Grimont F., Ryan M., et al. Shigella dysenteriae serotype 1 in west Africa: Intervention strategy for an outbreak in Sierra Leone. Lancet 362 August 30 (9385) (2003) 705-706
11. Parsonnet J., Greene K.D., Gerber A.R., Tauxe R.V., Vallejo Aguilar O.J., and Blake P.A. Shigella dysenteriae type 1 infections in US travellers to Mexico, 1988. Lancet 2 September 2 (8662) (1989) 543-545
12. Ahmed F., Clemens J.D., Rao M.R., Ansaruzzaman M., and Haque E. Epidemiology of shigellosis among children exposed to cases of Shigella dysentery: a multivariate assessment. Am J Trop Med Hyg 56 March (3) (1997) 258-264
13. Ries A.A., Wells J.G., Olivola D., Ntakibirora M., Nyandwi S., Ntibakivayo M., et al. Epidemic Shigella dysenteriae type 1 in Burundi: panresistance and implications for prevention. J Infect Dis 169 May (5) (1994) 1035-1041
14. Sarkar K., Ghosh S., Niyogi S.K., and Bhattacharya S.K. Shigella dysenteriae type 1 with reduced susceptibility to fluoroquinolones. Lancet 361 March 1 (9359) (2003) 785
15. Samandari T., Kotloff K.L., Losonsky G.A., Picking W.D., Sansonetti P.J., Levine M.M., et al. Production of IFN-gamma and IL-10 to Shigella invasins by mononuclear cells from volunteers orally inoculated with a Shiga toxin-deleted Shigella dysenteriae type 1 strain. J Immunol 164 February 15 (4) (2000) 2221-2232
16. Kotloff K.L., Taylor D.N., Sztein M.B., Wasserman S.S., Losonsky G.A., Nataro J.P., et al. Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults. Infect Immun 70 April (4) (2002) 2016-2021
17. Orr N., Katz D.E., Atsmon J., Radu P., Yavzori M., Halperin T., et al. Community-based safety, immunogenicity, and transmissibility study of the Shigella sonnei WRSS1 vaccine in Israeli volunteers. Infect Immun 73 December (12) (2005) 8027-8032
18. Coster T.S., Hoge C.W., VanDeVerg L.L., Hartman A.B., Oaks E.V., Venkatesan M.M., et al. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect Immun 67 July (7) (1999) 3437-3443
19. Katz D.E., Coster T.S., Wolf M.K., Trespalacios F.C., Cohen D., Robins G., et al. Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers. Infect Immun 72 February (2) (2004) 923-930
20. Venkatesan M.M., Hartman A.B., Newland J.W., Ivanova V.S., Hale T.L., McDonough M., et al. Construction, characterization, and animal testing of WRSd1, a Shigella dysenteriae 1 vaccine. Infect Immun 70 June (6) (2002) 2950-2958
21. Oaks E.V., and Turbyfill K.R. Development and evaluation of a Shigella flexneri 2a and S. sonnei bivalent invasin complex (invaplex) vaccine. Vaccine 24 March 20 (13) (2006) 2290-2301
22. Carpenter C.M., Hall E.R., Randall R., McKenzie R., Cassels F., Diaz N., et al. Comparison of the antibody in lymphocyte supernatant (ALS) and ELISPOT assays for detection of mucosal immune responses to antigens of enterotoxigenic Escherichia coli in challenged and vaccinated volunteers. Vaccine 24 May 1 (18) (2006) 3709-3718
23. Ahren C., Jertborn M., and Svennerholm A.M. Intestinal immune responses to an inactivated oral enterotoxigenic Escherichia coli vaccine and associated immunoglobulin A responses in blood. Infect Immun 66 July (7) (1998) 3311-3316
24. Hall E.R., Wierzba T.F., Ahren C., Rao M.R., Bassily S., Francis W., et al. Induction of systemic antifimbria and antitoxin antibody responses in Egyptian children and adults by an oral, killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine. Infect Immun 69 May (5) (2001) 2853-2857
25. Martindale J., Stroud D., Moxon E.R., and Tang C.M. Genetic analysis of Escherichia coli K1 gastrointestinal colonization. Mol Microbiol 37 September (6) (2000) 1293-1305
26. Kotloff K.L., Pasetti M.F., Barry E.M., Nataro J.P., Wasserman S.S., Sztein M.B., et al. Deletion in the Shigella enterotoxin genes further attenuates Shigella flexneri 2a bearing guanine auxotrophy in a phase 1 trial of CVD 1204 and CVD 1208. J Infect Dis 190 November 15 (10) (2004) 1745-1754
27. Ranallo R.T., Thakkar S., Chen Q., and Venkatesan M.M. Immunogenicity and characterization of WRSF2G11: a second generation live attenuated Shigella flexneri 2a vaccine strain. Vaccine 25 March 8 (12) (2007) 2269-2278
28. Teghanemt A., Zhang D., Levis E.N., Weiss J.P., and Gioannini T.L. Molecular basis of reduced potency of underacylated endotoxins. J Immunol 175 October 1 (7) (2005) 4669-4676
29. D'Hauteville H., Khan S., Maskell D.J., Kussak A., Weintraub A., Mathison J., et al. Two msbB genes encoding maximal acylation of lipid A are required for invasive Shigella flexneri to mediate inflammatory rupture and destruction of the intestinal epithelium. J Immunol 168 May 15 (10) (2002) 5240-5251